Patents by Inventor Eric G. Marcusson

Eric G. Marcusson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20100267813
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 31, 2008
    Publication date: October 21, 2010
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Targeting MicroRNAs for the Treatment of Liver Cancer
    Publication number: 20100267814
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Application
    Filed: October 29, 2008
    Publication date: October 21, 2010
    Applicants: REGULUS THERAPEUTICS INC., ROSETTA GENOMICS LTD.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric G. Marcusson, Noga Yerushalmi
  • Modulation of HIF1-beta expression
    Patent number: 7799764
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: September 21, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth Dobie
  • Identification of novel pathways, genes and promoter motifs regulating adipogenesis
    Patent number: 7759318
    Abstract: The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor/transcription factor-regulated genes. Methods for modulating the function of PPAR-? as well as PPAR-?-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: July 20, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ranjan Perera, Seongjoon Koo, Nicholas M. Dean, Eric G. Marcusson
  • MODULATION OF eIF4E EXPRESSION
    Publication number: 20100130589
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: August 31, 2009
    Publication date: May 27, 2010
    Inventors: Susan M. Freier, Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff, Bruce William Konicek
  • MODULATION OF HIF1 BETA EXPRESSION
    Publication number: 20100113573
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Application
    Filed: October 13, 2009
    Publication date: May 6, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth Dobie
  • Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
    Patent number: 7683036
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: March 23, 2010
    Assignee: Regulus Therapeutics Inc.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20090317907
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 30, 2008
    Publication date: December 24, 2009
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20090298174
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 30, 2008
    Publication date: December 3, 2009
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20090291906
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 30, 2008
    Publication date: November 26, 2009
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20090291907
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 30, 2008
    Publication date: November 26, 2009
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20090286969
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 30, 2008
    Publication date: November 19, 2009
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Modulation of HIF-1 beta expression
    Patent number: 7618947
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: November 17, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth W. Dobie
  • Modulation of eIF4E expression
    Patent number: 7601700
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 13, 2009
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • MODULATION OF eIF4E EXPRESSION
    Publication number: 20090192106
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: August 1, 2008
    Publication date: July 30, 2009
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Modulation of eIF4E expression
    Patent number: 7425544
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: September 16, 2008
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Modulation of HIF1? and HIF2? expression
    Patent number: 7217572
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: May 15, 2007
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier
  • Modulation of HIF1alpha and HIF2alpha expression
    Publication number: 20040220393
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1&agr; and/or HIF2&agr;. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1&agr; and HIF2&agr;. Methods of using these compounds for modulation of HIF1&agr; and/or HIF2&agr; expression and for diagnosis and treatment of disease associated with expression of HIF1&agr; and/or HIF2&agr; are provided.
    Type: Application
    Filed: November 21, 2003
    Publication date: November 4, 2004
    Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier
  • Antisense modulation of novel anti-apoptotic bcl-2-related proteins
    Publication number: 20040204380
    Abstract: Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.
    Type: Application
    Filed: May 12, 2004
    Publication date: October 14, 2004
    Inventors: Elizabeth J. Ackermann, C. Frank Bennett, Nicholas M. Dean, Eric G. Marcusson
  • Antisense modulation of Fas mediated signaling
    Publication number: 20040033979
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Application
    Filed: July 14, 2003
    Publication date: February 19, 2004
    Inventors: Nicholas M. Dean, Eric G. Marcusson, Jacqueline Wyatt, Hong Zhang